文献速递免疫规划卫生政策与健康促进

评估重组可传播疫苗的前景

Evaluating the promise of recombinant transmissible vaccines.
PubMed 文献 · Vaccine · 2017-12-24

可传播疫苗有望减少保护人群所需的接种工作量,重组可传播疫苗(RTV)因宿主内进化导致疫苗 revert 为载体形式时风险较低而受关注。研究构建数学模型检验疫苗与载体共享完美交叉免疫时RTV能否促进疾病管理,结果显示无交叉免疫时RTV可自主根除病原体或保护人群免受病原体入侵,存在交叉免疫时仅当持续辅以直接手工接种才能大幅减少控制或根除病原体所需的接种工作量。

要点

  • 无交叉免疫时,RTV可自主根除病原体或保护人群免受病原体入侵。
  • 存在交叉免疫时,RTV仅当持续辅以直接手工接种才能大幅减少接种工作量。
  • 估计载体与疫苗间交叉免疫程度是RTV设计的关键步骤。

核心结论

  • RTV在无交叉免疫时可自主根除病原体或保护人群免受病原体入侵。
  • 存在交叉免疫时,RTV仅当持续辅以直接手工接种才能大幅减少控制或根除病原体所需的接种工作量。
  • 估计载体与疫苗间交叉免疫程度是RTV设计的关键步骤,显示易再感染和弱交叉免疫的疱疹病毒载体有前景。

研究设计与样本

  • 研究构建数学模型检验重组可传播疫苗(RTV)在特定条件下能否促进疾病管理。

主要发现

  • 无交叉免疫时,RTV可自主根除病原体或保护人群免受病原体入侵。
  • 存在交叉免疫时,RTV仅当持续辅以直接手工接种才能大幅减少控制或根除病原体所需的接种工作量。

关键数值与推荐

  • 疫苗与载体共享完美交叉免疫时,RTV仅当持续辅以直接手工接种才能大幅减少控制或根除病原体所需的接种工作量。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Transmissible vaccines have the potential to revolutionize infectious disease control by reducing the vaccination effort required to protect a population against a disease. Recent efforts to develop transmissible vaccines focus on recombinant transmissible vaccine designs (RTVs) because they pose reduced risk if intra-host evolution causes the vaccine to revert to its vector form. However, the shared antigenicity of the vaccine and vector may confer vaccine-immunity to hosts infected with the vector, thwarting the ability of the vaccine to spread through the population. We build a mathematical model to test whether a RTV can facilitate disease management in instances where reversion is likely to introduce the vector into the population or when the vector organism is already established in the host population, and the vector and vaccine share perfect cross-immunity. Our results show that a RTV can autonomously eradicate a pathogen, or protect a population from pathogen invasion, when cross-immunity between vaccine and vector is absent. If cross-immunity between vaccine and vector exists, however, our results show that a RTV can substantially reduce the vaccination effort necessary to control or eradicate a pathogen only when continuously augmented with direct manual vaccination. These results demonstrate that estimating the extent of cross-immunity between vector and vaccine is a critical step in RTV design, and that herpesvirus vectors showing facile reinfection and weak cross-immunity are promising.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Basinski AJ, Varrelman TJ, Smithson MW, et al. Evaluating the promise of recombinant transmissible vaccines. Vaccine. 2017. PMID: 29279283. doi:10.1016/j.vaccine.2017.12.037

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。